| THE HOSPITAL FOR SICK CHILDREN Patent applications |
| Patent application number | Title | Published |
|---|
| 20120029168 | METHOD FOR AMELIORATING PAIN BY MODIFICATION OF NMDA RECEPTORS THROUGH INHIBITION OF SRC - The present invention provides a method for ameliorating inflammatory and/or neuropathic pain in a subject by modifying the activity of N-methyl-D-aspartate (NMDA) receptors in cells of the subject by inhibition of the interaction of the unique domain of the tyrosine kinase Src enzyme and the NMDA receptor complex. | 02-02-2012 |
| 20120021487 | METHOD OF TREATING GAUCHER DISEASE - Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof. | 01-26-2012 |
| 20110306045 | Method for Confirming a Diagnosis of Rolandic Epilepsy - A strong association between variants in Elongator Protein Complex 4, (ELP4) (specifically single nucleotide polymorphisms, SNPs) at the 11p13 locus on chromosome 11 and the centrotemporal sharp wave trait (CTS) has been discovered, which association has diagnostic significance for rolandic epilepsy. It has further been discovered that the 11p13 locus has a pleiotropic role in the development of speech motor praxis and CTS, which supports a neurodevelopmental origin for classic rolandic epilepsy (RE). | 12-15-2011 |
| 20110301105 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS - We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject. | 12-08-2011 |
| 20110251635 | USE OF REMOTE ISCHEMIC CONDITIONING FOR TRAUMATIC INJURY - The invention provides methods for reducing traumatic injury through the use of ischemic conditioning. | 10-13-2011 |
| 20110240043 | USE OF REMOTE ISCHEMIC CONDITIONING TO IMPROVE OUTCOME AFTER MYOCARDIAL INFARCTION - The invention provides methods for reducing the incidence and/or severity and/or delaying the onset of heart dysfunction/failure and improving overall survival through the use of remote ischemic per-conditioning and post-conditioning. | 10-06-2011 |
| 20110195985 | COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES - A method of treating a lysosomal storage disease comprises administering a pyrimethamine derivative to a subject in need thereof. | 08-11-2011 |
| 20110190807 | REMOTE ISCHEMIC CONDITIONING FOR TREATMENT AND PREVENTION OF RESTENOSIS - The invention provides methods for reducing the incidence and/or severity of restenosis through the use of remote ischemic conditioning. | 08-04-2011 |
| 20110091447 | LYMPHOCYTE CONTROL OF OBESITY AND INSULIN RESISTANCE - Methods for the treatment, inhibition, prevention, etc. of metabolic syndrome (MetSyn) and/or Type-2 diabetes (T2D) using a T cell activating antibody that stimulates activation and immunomodulation of T-cells to affect the immune environment of adipose tissue and improve insulin sensitivity. Also methods for the treatment, inhibition, prevention, amelioration, reversal, etc., of metabolic syndrome (MetSyn) and/or Type-2 diabetes (T2D) using leukemia inhibitory factor (LIF), or a functional portion thereof. Compositions administered to individuals having or at risk of developing MetSyn and/or T2D may include pharmaceutical compositions. Methods may also provide tolerogenic vaccines based on the administration of identified auto-antigens from individuals having or at risk of developing MetSyn and/or T2D. | 04-21-2011 |
| 20110053166 | STEM CELL EXPRESSION CASSETTES - A stem cell expression cassette, comprising a nucleic acid comprising a pluripotent stem cell specific promoter, and a tag sequence, wherein the pluripotent stem cell specific promoter and tag sequences are operatively linked, is provided. Also provided are methods of identifying and methods of selecting a pluripotent cell, using the stem cell expression cassette. | 03-03-2011 |
| 20100305607 | SYSTEM FOR PERFORMING REMOTE ISCHEMIC PRECONDITIONING - A system for remote ischemic preconditioning that includes a cuff, and actuator, and a controller that operates the actuator according to a treatment protocol. The treatment protocol includes a plurality of treatment cycles that each comprise cuff actuation, an ischemic duration, cuff release, and a reperfusion duration. | 12-02-2010 |
| 20100292619 | PERFORMANCE ENHANCEMENT - The invention provides methods for enhancing physical performance without requiring repetitive training. | 11-18-2010 |
| 20100287638 | NEURAL TUMOR STEM CELLS AND METHODS OF USE THEREOF - The present invention relates to the discovery that renewable stem cell lines can be derived from tumor cells and can be cultured in vitro. Accordingly, the invention provides neural tumor stem cell lines and cells from such cell lines. Because the cell lines retain characteristics of the tumors from which they are derived, the cells can be used in screening methods for identification of potential therapeutic agents and can be used to identify genetic markers which may be predictive for development of such tumors. Finally, such cells can be used to determine an appropriate therapeutic regimen for a patient suffering from a brain tumor. Cells from a patient's brain tumor can be cultured as described herein to create a cell line, and the relative effectiveness of a therapeutic agent against the cells can be tested to determine which agent or combination of agents is most effective in treating the patient's tumor. | 11-11-2010 |
| 20100239640 | SKIN-DERIVED PRECURSOR CELLS AND USES THEREOF - The invention features methods of inducing hair follicle formation in a mammal by transplantation of skin-derived precursors (SKPs) and keratinocytes into the skin of the mammal. The invention also features compositions and kits including SKPs and keratinocytes. In other aspects, the invention features methods for producing dermal sheets from SKPs, methods for using such sheets and dermal sheets produced by SKPs. | 09-23-2010 |
| 20100160799 | METHODS AND SYSTEM FOR PERFORMING REMOTE ISCHEMIC PRECONDITIONING - A system for remote ischemic preconditioning that includes a cuff, and actuator, and a controller that operates the actuator according to a treatment protocol. The treatment protocol includes a plurality of treatment cycles that each comprise cuff actuation, an ischemic duration, cuff release, and a reperfusion duration. | 06-24-2010 |
| 20100158333 | RESOLUTION IMPROVEMENT IN EMISSION OPTICAL PROJECTION TOMOGRAPHY - A method of reducing blur in an optical projection tomography (OPT) image comprises filtering the frequency space information of OPT image data to reduce the effects of out-of-focus data and defocused in-focus data and reconstructing the filtered OPT data. | 06-24-2010 |
| 20100119617 | MULTI-NUTRIENT MILK FORTIFIER - A multi-nutrient fortifier Total Randomized for supplementing breastfed infants is provided. The fortifier can be sterilized and can be formulated for delivery after hospital discharge. The fortifier is designed to supplement infants to meet the specific needs such as maintaining appropriate and safe levels of fat soluble vitamins and minerals, to incorporate vitamins normally requiring additional supplementation, such as vitamins A, D, E or iron for breastfed infants, to facilitate delivery of calcium and phosphorous salts. According to an embodiment of the invention, the fortifier can be in a concentrated liquid form, is sterile, and delivers greater than about 44% protein, by weight, and greater than about 17% protein, by weight, when analyzed in combination with breast milk. The fortifier can be used to improve growth and body composition of a breastfed infant post hospital discharge, such as a low birth weight infant, a post-surgical infant, or an ill term-born infant. | 05-13-2010 |
| 20100022907 | Methods based on fluctuations in cortical synchronization - A method of identifying a site of injury in a pediatric patient with brain injury is provided which comprises obtaining an electroencephalogram signal on the patient. The identification of phase synchrony within the signal is indicative of the site of brain injury. Electroencephalogram signals may also be used to determine prognosis of a pediatric patient in a coma in which an increase in the temporal variability of phase synchronized EEG signals over time is indicative of an improvement in the patient. | 01-28-2010 |
| 20100009346 | Lafora's disease gene - A novel gene (EPMZA) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EMP2A have been found that co-segregate with Lafora's disease. | 01-14-2010 |
| 20090312255 | STIMULATION OF TRPV1+ SENSORY NEURONS TO CONTROL BETA-CELL STRESS AND ISLET INFLAMMATION IN DIABETES - The present invention provides a method of altering the function of TRPV1+ sensory afferent neurons in the pancreas as a way of treating, managing, alleviating, etc., the symptoms and/or underlying causes of diabetes or abnormal glucose metabolism by increasing the release of neuropeptides, such as substance P (sP) or other tachykinin peptide, in the pancreas. This may be achieved by injecting a TRPV1 agonist, such as a capsaicinoid compound or capsaicin analog, or a neuropeptide, such as sP or other tachykinin peptide, directly into the pancreas, or alternatively, by stimulating one or more intercostal and/or subcostal nerves of spinal nerves derived from one or more thoracic segments T8 through T12 by chemical, electrical, surgical, mechanical, etc., methods. | 12-17-2009 |
| 20090311704 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OF AUTOPHAGIC VACUOLAR MYOPATHY - Transmembrane V-ATPase proton pump complexes regulate pH of extracellular space or intracellular compartments of cells. V-ATPase complexes are ubiquitous in cells across species. A human orthologue of yeast vma21, LOC203547 (VMA21), is likely involved in the assembly of the V-ATPase. Hypomorphic mutations of VMA21 are identified from XMEA patients. Methods to diagnose and/or distinguish between different forms of vacuolar or vacuolated myopathy in an individual or patient are provided based either on the sequence of the VMA21 gene and/or the level and/or activity of the V-ATPase complex. Compositions of the present invention may comprise DNA, RNA, or protein molecules corresponding to all or a portion of VMA21 and including one or more of the mutations in VMA21 identified. Cultured cells or cell lines having one or more mutations in the VMA21 gene derived from patients having a form of vacuolar or vacuolated myopathy are provided. | 12-17-2009 |
| 20090233361 | Tissue bioreactor - A bioreactor comprising, two chambers in fluid communication, a tissue matrix held in place between, and separating, the two chambers, each side of the tissue matrix in fluid communication with one of the two chambers, each chamber comprising at least one port. | 09-17-2009 |
| 20090221511 | TRPV1 + SENSORY NEURONS CONTROL OF BETA-CELL STRESS AND ISLET INFLAMMATION IN DIABETES - A process is disclosed for controlling inflammatory tissue access through release of neuropeptides, such as substance P (sP), to insulin-responsive sensory neurons, whereby simultaneous control of insulin sensitivity/resistance is manifested. In models of Type 1 and Type 2 diabetes, sensory afferents, in particular TRPV1, have fundamental roles in insulin/glucose homeostasis, islet physiology and autoimmune tissue inflammation. By manipulation of the TRPV1 neuro-β-cell circuit or enhancement of pancreatic sP levels, normalization of insulin resistance, clearance of inflammation and prevention of both Type 1 and Type 2 diabetes is realized. | 09-03-2009 |
| 20090163500 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS - The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds. | 06-25-2009 |
| 20090155789 | GENES FROM THE 20Q13 AMPLICON AND THEIR USES - The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases. | 06-18-2009 |
| 20090098565 | MeCP2E1 gene - The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders. | 04-16-2009 |
| 20090094703 | Novel medulloblastoma-forming cell line - Isolated medulloblastoma-forming clonogenic cells are provided which are useful to form stable cell lines as well as a non-human animal models of medulloblastoma that mimic human medulloblastoma, thereby providing a means to screen for candidate therapeutic compounds. | 04-09-2009 |
| 20090081672 | GENES FROM THE 20Q13 AMPLICON AND THEIR USES - The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases. | 03-26-2009 |
| 20090075960 | Method of treating gaucher disease - Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof. | 03-19-2009 |
| 20090036387 | NOVEL CHEMICAL ENTITIES AFFECTING NEUROBLASTOMA TUMOR-INITIATING CELLS - Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that include these chemical entities are also provided for the treatment of neuroblastoma. These pharmaceutical preparations are suitable for the treatment of humans, and are particularly suited for the treatment of children of 12 years of age or younger having neuroblastoma. The compositions and pharmaceutical preparations posses reduced normal cell cytotoxicity. The compositions and pharmaceutical preparations may be used alone or together with other conventional neuroblastoma preparations as part of a clinical regimen in the treatment and management of neuroblastoma. | 02-05-2009 |
| 20080206753 | Methods for Cancer Prognosis - A method for assessing prognosis in a subject having a breast tumor comprises determining the level of expression of at least one Notch receptor gene, Notch ligand gene or Notch signaling target gene. A method of treating a subject suffering from a breast tumor associated with increased Notch signaling comprises administering to the subject an effective amount of an inhibitor of Notch signaling. | 08-28-2008 |
